CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
Rhea-AI Summary
CervoMed (NASDAQ: CRVO) completed a Phase 1 healthy volunteer study evaluating a new, stable crystal form of neflamapimod and selected 50 mg three times daily (TID) as the dosing regimen for its planned Phase 3 trial in dementia with Lewy bodies (DLB).
The company says the stable crystal form's pharmacokinetic profile largely overlaps with the clinically active DP Batch B from the Phase 2b extension; dose is increased to ensure target plasma concentrations are achieved.
Positive
- 50 mg TID dose chosen to match active exposure
- New controlled process yields a single stable crystal form
- Phase 1 PK shows overlap with clinically active DP Batch B
Negative
- Stable form has lower solubility requiring a higher dose
- Prior polymorph conversion caused decreased bioavailability in earlier batch
Market Reaction – CRVO
Following this news, CRVO has gained 6.98%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.8% during the session. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $4.29. This price movement has added approximately $2M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves (e.g., OVID up 5.59%, ANEB down 17.7%), while only one momentum-scanned peer (QNCX) was down, pointing to stock-specific drivers for CRVO.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Phase 2b extension data | Positive | +6.3% | Reported positive extension results with new capsule batch improving clinical outcomes. |
| Dec 10 | Topline Phase 2b data | Negative | -78.9% | Disappointing topline Phase 2b results with primary endpoint not met and low exposure. |
| Dec 10 | Orphan Drug Designation | Positive | +14.7% | Announced FDA Orphan Drug Designation for neflamapimod in frontotemporal dementia. |
| Nov 04 | CTAD conference data | Positive | -2.6% | Highlighted significant GFAP reduction and strong statistical power in ongoing Phase 2b study. |
| Oct 15 | Trial milestone update | Positive | +1.9% | Announced Last Patient Last Visit in Phase 2b RewinD-LB trial and on-track timelines. |
Clinical-trial news for CRVO has usually moved the stock in the same direction as the news tone, with one notable case where positive conference updates coincided with a small decline.
Over the past year, CervoMed has built a steady clinical narrative around neflamapimod in dementia with Lewy bodies. Earlier clinical releases, including positive extension data on Mar 10, 2025 and Orphan Drug Designation on Nov 27, 2024, produced mainly positive price reactions. The sharp selloff on Dec 10, 2024 followed disappointing topline Phase 2b data, highlighting sensitivity to efficacy and exposure signals. Today’s announcement on formulation and dosing for a planned Phase 3 trial fits this ongoing effort to optimize exposure after prior underdosing concerns.
Historical Comparison
Past clinical-trial headlines for CRVO averaged a -11.73% move. Today’s formulation/dosing update with a +3.08% pre-news gain appears more muted and directionally opposite to that average.
Clinical updates have progressed from Phase 2b topline and extension data toward refining exposure and capsule performance, with the current news advancing dosing and formulation choices ahead of a planned Phase 3 DLB trial.
Market Pulse Summary
The stock is up +7.0% following this news. A strong positive reaction aligns with prior instances where encouraging clinical updates on neflamapimod supported upside moves. The company previously faced a major setback from underexposure in Phase 2b, so the focus on PK matching and a 50mg TID regimen may have been seen as de-risking. Investors would still need to weigh upcoming Phase 3 execution risks and the stock’s position well below its $16.94 52-week high.
Key Terms
bioavailability medical
pharmacokinetics medical
pk medical
phase 3 medical
phase 2b medical
AI-generated analysis. Not financial advice.
Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process
Pharmacokinetic profile of the new, stable crystal form of neflamapimod largely overlaps with the therapeutically active drug product used in Phase 2b trial extension
To ensure that plasma drug concentrations associated with therapeutic activity are achieved, dosing regimen in the planned Phase 3 trial in dementia with Lewy bodies will be 50mg TID of the stable, crystal form of neflamapimod
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (CervoMed or the Company) (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that it has successfully completed a Phase 1 healthy volunteer study designed to evaluate the pharmacokinetics (PK) of drug product (DP) containing only a new, stable crystal form of neflamapimod and related updates regarding its planned Phase 3 trial in dementia with Lewy bodies (DLB).
Following its evaluation of the study’s results, the Company has selected 50mg of the stable crystal form of neflamapimod three times per day (TID) as the dose and dosing regimen for its planned Phase 3 study in patients with DLB. While the PK profiles of 40mg of DP Batch B and 40mg of the stable crystal form of neflamapimod are largely overlapping, the dose will be increased to 50mg in the Company’s planned Phase 3 trial to ensure that the dosing regimen achieves the plasma drug concentrations observed with the neflamapimod drug product batch that demonstrated significant clinical and biomarker activity in the extension phase of the Phase 2b RewinD-LB trial (DP Batch B).
“The selection of the dosage strength for our planned Phase 3 trial reflects more than a year of focused work by our Chemistry, Manufacturing and Controls team to understand and address the cross-batch variability and underperformance observed with the ineffective drug product batch (DP Batch A) in the RewinD-LB Phase 2b trial,” said John Alam, MD, Chief Executive Officer of CervoMed. “By aligning plasma drug concentrations with those achieved from the clinically active DP Batch B capsules and incorporating a stable crystal form of neflamapimod that mitigates prior manufacturing challenges, we believe we are well positioned to replicate the positive clinical outcomes observed in the RewinD-LB trial in our planned Phase 3 trial.”
"The process historically used to manufacture neflamapimod produced drug substance containing multiple solid-state forms, also called polymorphs,” said Marco Verwijs, PhD, Executive Vice President of Technical Operations at CervoMed. “With prolonged storage, the less-stable, higher-solubility polymorphs converted into a more stable but lower-solubility form, resulting in decreased bioavailability when administered to patients."
Dr. Verwijs continued, "To address this, we have developed and implemented a controlled manufacturing process that only produces the stable crystal form of neflamapimod. While the pharmacokinetic profile of this formulation is largely comparable to the clinically active DP Batch B used in the extension phase of the RewinD-LB trial, we plan to increase the dose to account for its solubility profile and to target the plasma drug concentrations seen with DP Batch B. As a result, we intend to move forward with a 50mg TID dosing regimen of neflamapimod in our planned Phase 3 trial.”
Additional information regarding these results and comparative pharmacokinetic data are being made available in the Company’s corporate presentation on the “Events and Presentations” page of CervoMed’s website at www.cervomed.com.
About Neflamapimod
Neflamapimod is an investigational, orally administered small-molecule drug that readily crosses the blood–brain barrier and selectively inhibits the alpha isoform of p38 MAP kinase, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, recovery after ischemic stroke, and primary progressive aphasia.
In non-clinical studies, neflamapimod restored synaptic function within the basal forebrain cholinergic system, the brain region most affected in DLB. Across Phase 1 and 2 clinical trials involving more than 800 participants, the drug has been generally well tolerated and demonstrated consistent signals of efficacy. In the 91-patient Phase 2a AscenD-LB trial, neflamapimod significantly improved dementia severity and functional mobility in patients with DLB. Results from the 159-patient Phase 2b RewinD-LB trial, a 16-week randomized, double-blind, placebo-controlled trial followed by a 32-week open-label extension, further supported neflamapimod’s potential to deliver meaningful clinical benefit, improving both cognitive and functional outcomes and showing a positive effect on a key blood biomarker of neurodegeneration during the extension phase. Across both studies, the greatest benefits were observed in patients without Alzheimer’s disease (AD) co-pathology. Collectively, these findings underscore the therapeutic promise and scientific validity of neflamapimod as a potential treatment for DLB and other degenerative brain disorders.
About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology. The Company plans to initiate a global, pivotal Phase 3 trial in patients with DLB, enriched for those without AD co-pathology, in the second half of 2026, subject to available funding.
Forward-Looking Statements
This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the plasma drug concentrations that will be achieved with neflamapimod treatment in any of the Company’s future clinical trials, including treatment with the stable, crystal form of neflamapimod; that the stable, crystal form of neflamapimod will have any particular pharmacokinetic profile or achieve any specific plasma drug concentrations, including whether such profile or concentrations will replicate those observed in any prior clinical trial or nonclinical study; the therapeutic potential of neflamapimod in DLB or any other indication, including the degree of sustainability of any therapeutic effects; the anticipated timing and achievement of clinical and development milestones, including the Company’s initiation of the Company’s planned Phase 3 trial in DLB patients without AD co-pathology and the announcement of any data therefrom; any other expected or implied benefits or results, including the extent (if any) to which neflamapimod may demonstrate efficacy or other clinical or biomarker improvements in patients; and the Company’s need to acquire sufficient funding, including funding for its planned Phase 3 trial. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources, the availability of additional funds on acceptable terms, and the Company’s ability to continue as a going concern; the results of the Company’s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) on March 17, 2025, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.
Contacts:
Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431
Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902
FAQ
What dosing regimen did CervoMed (CRVO) select for the planned Phase 3 DLB trial?
Why is CervoMed (CRVO) using a stable crystal form of neflamapimod in Phase 3?
How do the pharmacokinetics of the stable crystal form compare to DP Batch B for CRVO's drug?
What manufacturing issue did CervoMed (CRVO) address before the Phase 3 plan?
Where can investors find the comparative pharmacokinetic data CervoMed (CRVO) mentioned?
